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O cancro da mama é uma doença heterogênea complexa 
e uma das principais causas de morte entre as mulheres. 
Muitos estudos têm tentado determinar se ácidos gordos 
(FA) saturados, monoinsaturados e polinsaturados têm 
efeitos diferentes sobre o desenvolvimento de cancro da 
mama. No entanto o papel dos diferentes FAs da dieta no 
lipidoma de células de cancro da mama não é 
completamente compreendido. O objetivo deste trabalho 
foi avaliar se o lipidoma da linha celular T-47D de cancro 
da mama se altera com diferentes FAs da dieta e 
correlacionar essas alterações com efeitos na proliferação 
e apoptose celulares. As alterações lipídicas induzidas 
pela presença de 1 ug / mL de ácido oleico (OA1) ou 1 
ou 2 ug / ml de ácido linoleico (LA1 ou LA2, 
respetivamente) de ácido in vitro foram estudadas através 
de uma análise lipidómica com base em técnicas tais 
como TLC, para a separação e quantificação de classes 
de fosfolípidos (PLs) e GC-MS, para separação e 
quantificação dos FAs. Os triglicerídeos (TGs) e 
colesterol (CHL) totais foram quantificados utilizando 
métodos colorimétricos. Além disso, a viabilidade 
celular e a apoptose também foram avaliadas. A análise 
de classes de PL permitiu observar alterações 
significativas nas classes de fosfatidiletanolamina (PE), 
fosfatidilserina (PS) nas células suplementadas com LA1 
e LA2, respetivamente, e lisofosfatidilcolina (LPC) nas 
células suplementadas com OA1. Observou-se ainda um 
aumento do FA 18:2 no tratamento com LA. Além disso, 
os TGs mostraram uma diminuição no tratamento com 
LA2. Os ensaios de viabilidade e apoptose mostraram 
que LA1 e LA2 estimulam o crescimento celular e que 
OA2 estimula a apoptose. Este trabalho contribui para 
uma melhor compreensão da influência dos FAs da dieta 
no lipidoma de células T-47D e mostra que as alterações 
no lipidoma celular estão associadas a um aumento do 
metabolismo e crescimento celular nas células 
suplementadas com LA e a um aumento da apoptose em 
células suplementadas com OA. Essas descobertas 
podem levar a novas perspetivas na identificação de 
estratégias específicas que podem ser úteis para 
compreender o processo envolvido na progressão do 
cancro da mama. No entanto, mais estudos são 
necessários para concluir sobre como os diferentes 
lípidos podem promover estes efeitos. 
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Breast cancer is a complex heterogeneous disease and 
one of the leading causes of death among women. Many 
studies have tried to determine if saturated, 
monounsaturated and polyunsaturated fatty acids (FA) 
have different effects on the development of breast 
cancer. However, the role of different dietary FAs in 
lipidome of breast cancer cells is not completely 
understood. The aim of this work was to establish if 
lipidome of breast cancer T47-D cell line differs with 
different dietary FAs and correlate this findings to effects 
in proliferation and apoptosis. The lipid changes in 
lipidome induced by the presence of 1 µg/mL oleic acid 
(OA1) or 1 or 2 µg/mL linoleic (LA1 or LA2, 
respectively) acid in vitro were study through a lipidomic 
analysis, based on techniques such as TLC and GC-MS. 
TLC allowed the separation and quantification of 
Phospholipid (PL) classes and GC –MS allowed the 
separation and quantification of FAs. TGs and CHL were 
quantified. Also, cell viability and apoptosis were 
evaluated. PL class analysis showed significant 
alterations in phosphatidylethanolamine (PE), 
phosphatidylserine (PS) in the medium with LA1 or 
LA2, respectively and lysophosphatidylcholine (LPC) in 
the medium with OA1. GC-MS showed an increase of 
18:2 in the treatment with LA. Further TG showed a 
decrease on LA2 treatment and viability and apoptosis 
assays showed that LA1 and LA2 stimulate cell growth 
and OA2 stimulated apoptosis, respectively. This work 
contributes to a better understanding of the influence of 
dietary FAs on the lipidome of T-47D cells and shows 
that alterations in cellular lipidome are associated to 
changes in cell number and apoptosis. These findings 
may lead to new perspectives in the identification of 
specific targets that may be helpful to understand the 
process behind breast cancer growth. However, more 
studies are necessary to conclude about how different 
lipid molecules promote these effects.   
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I. Introduction 
1. The mammary gland 
The mammary gland is a very specialized exocrine gland, located in the breast, with 
the specific function of synthesizing, secreting, and delivering milk to the newborn (1). It 
is composed by multiple types of cells that together form complex interaction networks 
required for the proper development of the organ (2).   
The completely developed breast has 15 to 20 sections (the lobes), and each lobe is 
made of many smaller sections (lobules) that are composed by alveoli, where milk is 
produced and secreted through a system of ducts that transport the milk from the alveoli 
to the nipple. Ducts terminate in terminal duct lobular units (TDLU), the anatomical and 
functional units of the breast (Figure 1). Two cellular compartments contribute to the 
gland: the epithelium and the surrounding stroma (e.g. endothelial cells, fibroblasts, 
myofibroblasts, and leukocytes), which are derived from ectoderm and mesoderm, 
respectively (3). The epithelial cells that compose the gland are arranged in two layers, 
an inner luminal epithelial layer and an outer myoepithelial layer (4). The luminal cells 
are responsible for producing milk during lactation, while the myoepithelial cells in 
contact with the basement membrane assist in milk ejection during lactation and provide 
structural support to the lobules (5). 
 
 
 
Figure 1. Schematic representation of the anatomy of the breast. Adapted from 
www.my-breast-cancer-guide.com/what-is-breast-cancer.html 
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The mammary gland, unlike most other organs, is not fully formed at the time of 
birth, reaching its full differentiation only during a pregnancy/lactation cycle, via 
hormonal influences. These influences promote drastic modifications in the anatomy of 
the gland, resulting in the remodeling of the gland into a milk-secretory organ (1). There 
are key stages in mammary development that exhibit considerable structural and 
functional variations throughout lifetime, particularly during puberty, normal menstrual 
cycle, pregnancy and lactation, and at menopause (6,7). Until puberty only a rudimentary 
ductal system exists. It is at the beginning of puberty, that more dynamic and pronounced 
changes in the breast occur with the establishment of menstrual cycle regulated by the 
ovarian and pituitary hormones (8). In the first half of the menstrual cycle the lobules are 
relatively quiescent. After ovulation, under the influence of female sex hormones, cell 
proliferation increases and so do the number of alveoli in each lobule (estrogen leads to 
proliferation of ductal cells and progesterone leads to increased proliferation and 
differentiation of alveolar cells). Upon menstruation, the decrease in the levels of estrogen 
and progesterone induces regression of the lobules and the disappearance of the stromal 
edema. Only with the onset of pregnancy the breast becomes completely mature and 
functional. Lobules increase progressively in number and size. Immediately after the baby 
is born, the luminal cells of the lobules produce colostrum, which then changes to milk. 
Cessation of lactation after weaning leads to extensive apoptosis of epithelial cells and 
tissue remodeling and the total breast size decreases considerably but full regression does 
not occur (9). Finally, in involution, being triggered by a declining of ovarian function 
and by a decrease in circulatory levels of estrogen and progesterone, the lobules and their 
specialized stroma continue to regress and atrophy and the adipose tissue increases (1).  
A balance between proliferation, differentiation, and death in the stem-cell 
population and throughout the cells of the mammary gland is critical for normal 
development. Alterations of normal proprieties of cells derived from a series of molecular 
events can lead to breast cancer. 
 
2. Breast cancer 
Breast cancer is a complex heterogeneous disease and one of the leading causes of 
death among women in the world, despite the significant advances in diagnosis and 
treatment. The manifold unresolved problems that remain are related to prevention, 
diagnosis, tumor progression and recurrence, treatment and therapeutic resistance. It is 
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very difficult to overcome these problems, because breast cancer is not a single disease 
but a highly heterogeneous collection of different diseases which affect the same 
anatomical organ and is originated in the same anatomical structure, TDLU (10,11). The 
causes of breast cancer are not yet fully known, although a number of risk factors that 
modulate the development of breast cancer have been identified. Among the risk factors, 
the genetic causes associated to familial forms of breast cancer account for only 5-10% 
of breast cancer. Therefore, most of the risk factors leading to breast cancer development 
are either environmental or related to life-style (12). 
Breast cancer can be classified taking into consideration different aspects such as, 
histopathology, grade of the tumor, stage of the tumor and, protein and gene expression. 
Histopathologic evaluation of a breast cancer by biopsy studies is necessary to provide 
the diagnosis of the tumor. Most breast cancers are derived from the epithelium lining the 
ducts or lobules, and these cancers are classified as ductal or lobular carcinoma, 
respectively. The most common type of breast cancer is ductal cancer. Cancers also are 
classified as non-invasive (in situ), that refers to cancer that confine itself to the tissue 
compartment where it initially developed and as invasive (infiltrating), that has a tendency 
to spread (metastasize) to other areas of the breast and/or other regions of the body 
(13,14); the grade of the tumor is a system that is based on the loss of differentiation 
capacity and it’s divided into three distinct grades: Grade I - well differentiated (is low 
grade and resembles normal tissue), Grade II - moderately differentiated (intermediate 
grade) and Grade III - poorly differentiated (is composed of disorganized cells and, 
therefore, does not look like normal tissue). A higher histological grade corresponds to a 
worse prognosis (15); the stage of the tumor that is based on tumor size is a prognostic 
factor with a high impact. The larger the size of the tumor, the greater the probability of 
occurrence of clones with the ability to metastasis and consequently the worse is the 
prognosis; the molecular classification of breast cancer by gene-expression profiling 
established major breast intrinsic subtypes: The luminal A and B (expressing estrogen 
receptors; ER), the HER2-overexpressing (HER2-OE), claudin-low and basal-like 
(16)(14). Such classification is useful because the patients, in general, are treated 
according to the type of receptors that cells express (i.e. ER antagonists, HER2 
inactivating antibodies). Luminal type can have expression of estrogen receptor (ER), 
progesterone receptor (PR) and varying degrees of human epidermal growth factor 
receptor 2 (HER2). Luminal A is characterized by the expression of ER and PR in cancer 
cells, whereas the luminal B is characterized by positivity of ER and PR together with 
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HER2 overexpression and/or high rates of cell proliferation (15,17). HER2-OE tumours 
are negative for hormonal receptors and overexpress HER2 protein (associated with 
HER2/neu gene amplification)(15). Basal -like tumors are the less differentiated and are 
characterized by the absence of ER, PR and HER2 (also called “triple-negative”) and 
presence of basal cytokeratins, and highly associated with specific aggressive histological 
features and poor patient survival (18). Claudin-low subtype, is mostly triple negative but 
with less cell – cell adhesion proteins and frequent infiltration of lymphocytes (16). Each 
of this four aspects (histopathology, grade of the tumor, stage of the tumor and, protein 
and gene expression), influences the prognosis and the therapies that are chosen for 
treatment.  
As mentioned above, breast cancer is a cellular disease characterized by 
uncontrolled cell proliferation that can be spread to various tissues in the body through a 
process known as metastasis. This process consists of several steps that need to be 
completed successfully to form a metastatic tumor (Figure 2).  
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Figure 2. Tumor metastasis step-by-step process. a. cellular transformation and tumor 
growth; b. extensive vascularization of the tumor; c. local invasion of the host stroma by 
some tumor cells; d. detachment and embolization of single tumor or aggregates and the 
cell tumors that survive to the immune system become trapped in the capillary beds of 
distant organs; e. extravasation occurs; f. proliferation within the organ completes the 
metastatic process. Adapted from (19). 
 
In the process of invasion and metastasis, tumor cells leave its original location 
(primary tumor) to a new part of the body. As cancer cells divide, they can invade and 
grow directly into the surrounding tissue or structures (direct extension), but they can also 
spread by breaking away from a breast tumor. If the cancer cells are not detected by the 
immune system, they can enter into the bloodstream (blood vessels) or lymphatic system 
(lymph vessels). Once in the circulation, cells can be transported over long distances 
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reaching other parts of the body (20). At particular sites, depending on the type of cancer, 
cells adhere to blood vessel walls, extravasate and seed in target organs. Some cells 
remain dormant for a long time before they start the formation of metastatic foci (19).  
It is probable that the interaction with the microenvironment contributes to the 
behavior of tumor cells and a major component is the extracellular matrix (ECM) (21) . 
The ECM consists of collagens, laminins and fibronectin and serves as structures which 
cells can attach and migrate. Cell – cell and cell – extracellular matrix (ECM) interactions 
are very important in the control of progression and migration of tumor cells and these 
interactions are mediated by proteins known as cell adhesion molecules (CAMs) (21,22). 
CAMs, a diverse system of transmembrane glycoproteins, are located on the cell surface 
and can be classified into five families including immunoglobulin superfamily, integrins, 
cadherins, selectins and CD44. These receptor proteins are composed by three domains: 
an intracellular domain which interacts with the cytoskeleton, a transmembrane domain 
and an extracellular domain that interact with other CAMs or the ECM allowing cells to 
communicate (22). To be functional they need to be activated, so cadherins and integrins 
need to form clusters. The cluster formation begins with the grouping of many CAM 
molecules in the plasmatic membrane, allowing the molecules to bind their ligands with 
higher strength. Formation of clusters and CAM activation allows them 
to transduce information from the ECM to the cell as well as reveal the status of the cell 
to the outside, allowing rapid and flexible responses to changes in the environment. 
Alterations on CAMs play an important role in tumor dissemination, because migration 
of cancer cells is critically regulated by physical adhesion of cells to each other and to 
their non-cellular surroundings. Loss of intercellular adhesion allows malignant cells to 
detach and to escape from the primary mass (22). Gaining a more motile and invasive 
phenotype, these cells secrete matrix metalloproteinases (MMP) which degrades the 
collagen of the ECM breaking through the cellular membrane that surrounds the tumor, 
allowing the tumor cell to migrate towards the blood or lymph vessels and eventually 
invade and metastasize to distal organs (23). 
Changes in membrane lipid composition have been reported in breast cancer. This 
changes in the lipid of the cell can regulate function and availability of intrinsic membrane 
proteins such as CAMs, thus affecting inside out and outside in cell signaling. This issue 
will be talked about further in the next section. 
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3. Lipids 
 
Lipids are essential components of the cell and play multiple and distinct roles in 
cellular functions. There is a great diversity of lipids, with very different structure and 
functions. The majority of the lipids of the cells form a lipid bi-layer whose characteristics 
are essential for the structural integrity and functionality of the cell membrane. Membrane 
lipids, particularly phospholipids (PLs), play key roles in protein assembly, allowing 
protein trafficking and anchoring to the membrane and provide a hydrophobic 
environment for membrane proteins function and interaction (24). The lipids of the 
membrane are involved in signal transduction. Besides, lipids are also energy storage 
molecules. For all these reasons, lipids are nowadays considered important players in 
membranes and in signalling, not only due to their own functions, but also for 
conditioning the functions of proteins in the cells (24). Thus it has become very important 
to deepen the knowledge concerning lipid profiles and lipid metabolism as well as how it 
changes with disease.  
Traditionally lipids are defined based on their solubility, since they are insoluble in 
water and soluble in organic solvents (such as chloroform, ether, acetone, among others). 
They also have in common the presence of long chains of hydrocarbons. However the 
diversity of lipids is so large that does not allow a simple definition. In fact a recent 
classification reports 8 classes based on their chemical structure: fatty acids (FAs), 
glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, polyketides, prenol 
lipids and sterol lipids (25). Several classes are divided into subclasses and each class 
embraces a molecular diversity of species due to the different combinations of distinct 
FAs with different length and instauration/saturation.  
One of the main classes of lipid membranes are the PLs, amphipathic compounds, 
that are the major component of most biological membranes of all cell forming lipid 
bilayers (Figure 3) (26). Also cholesterol (CHL), the principal constituent of group of 
sterol lipids is an important constituent of membrane, being signaling regulation and 
membrane fluidity their main function (26).  
Glycerolipids include fundamentally monoacylglycerols, diacylglicerols (DAG) 
and triglycerides (TG). TGs are an esters derived from glycerol and three FAs, and they 
are very abundant in nature, being the main constituents of animal fat. TGs have an 
important role in cellular energy storage (27). 
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Figure 3. Illustration of a eukaryotic cell membrane. Adapted from 
http://einstein.sc.mahidol.ac.th/~bionanotech/7_Research_Page/ResProj_9/Physics_of_
Cell_Membrane.html 
 
 
3.1. Fatty acids 
 
FAs are the basic elements of most lipids. Biological systems can have free FAs 
(FFAs), or they can be esterified into other lipids classes. FFAs are carboxylic acids 
represented by the formula R-COOH, where R is usually a chain of hydrocarbon radical, 
un-ramified and, in general, these FAs have an even number of carbon atoms joined by 
single or double bonds. FAs can be classified according to the degree of saturation, total 
number of carbons and whether they are synthetized by the organism by de novo 
lipogenesis or must be consumed in the diet (essential FAs) (28,29). 
In the circulation, FAs are transported bound to albumin or as part of lipoproteins 
and they are taken up into cells mainly by protein carriers in the plasma membrane and 
then transported in the cell via fatty acid-binding proteins (FABP). Inside the cells, FFAs 
are activated (acyl-CoA) to then be transported to the mitochondria or peroxisomes or b-
oxidation to obtain energy, or to the endoplasmic reticulum for esterification to different 
lipid classes. Acyl-CoA or certain FFAs may bind to transcription factors that regulate 
gene expression or may be converted to signaling molecules (eicosanoids) (29) (Figure 
4). 
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Figure 4. The metabolism of FAs. FAs can come from the diet or de novo lipogenesis 
once they are activated (acyl-CoA), they are either incorporated into membrane lipids 
(PL), into storage lipids (TG and CHL esters) or suffer oxidation in mitochondrion or 
peroxisome to form energy. Also, FAs can be important for other functions in the cell 
such as ligands capable of activating gene expression. Adapted from (29). 
 
 The FAs can be subdivided into 3 classes depending on the degree of saturation. 
They can be saturated FAs (SFA), which have no double bonds, monosaturated FAs 
(MUFA) that have one double bond, and polyunsaturated FAs (PUFA) that have two or 
more double bonds. The double bonds of naturally occurring unsaturated FAs are very 
often of the cis orientation. This means that the hydrogen atoms attached to the double 
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bonds are on the same side. However if the hydrogen atoms are on opposite sides, the 
configuration is termed trans(29). 
 The SFA can occur in many kinds, which differ mainly in the number of carbon 
atoms such as butyric (C4:0), caproic (C6:0), caprylic (C8:0), capric (C10:0), lauric 
(C12:0), myristic (C14:0), palmitic (C16:0), and stearic (C18:0) acids. C16:0 is 
usually considered the most abundant SFA in nature, and it is found in appreciable 
amounts in the lipids of animals, plants and lower organisms. C18:0 is the second 
most abundant  SFA in nature (29). Relatively high proportions of stearic acid are 
subjected to enzymatic desaturation (to oleic acid), in comparison to other SFAs. 
 The most common MUFA is oleic acid (OA) and it is present in considerable 
quantities in both animal and plant sources. These FA is obtained through diet but can 
be also synthesized by mammals. The biosynthesis of OA involves the action of 
enzyme CoA 9-desaturase. This enzyme, present in plants and animals, induces a 
double bond in the ninth position from the hydrocarbon terminal, converting C18:0 in 
OA (C18:1, n-9) (29). 
 The PUFAs are classified in three families according to the position of the first 
double bond from the methyl group terminal of the molecule (n-9, n-6 and n-3) (30). 
Linoleic acid (LA) (18:2 n-6) and alpha-linolenic acid (ALA) (C18:3 n-3) are essential 
FAs (EFAs) (Figure 5). EFAs can only be obtained through the diet, due to the 
absence, in mammals, of their biosynthetic enzymes (28). Humans are able to convert 
LA and ALA to more physiologically active FAs through a series of elongation and 
desaturation reactions (28). LA can be converted to arachidonic acid (AA; 20:4 n-6) 
and ALA converted to eicosapentaenoico acid (C20:5 n-3)(EPA)  and 
docosapentaenoic acid (C22: 6 n-3) (DHA)  (Figure. 5) (29). FA of different families 
do not interconvert. 
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Figure 5. Biosynthetic pathways of Omega-3 and omega-6 PUFAs with the 
indication of the main enzymes that participate in these biosynthetic routes. Each 
metabolic sequence competes for the same enzyme systems, with the affinity being 
greater for n-3 FA than n-6 FA. Adapted from (29). 
 
 
The unsaturated FAs are incorporated into the sn-2 position of membrane PLs (that 
will be reported latter), with degrees of affinity to respect the order n-3> n-6> n-9 
differently influencing the structure and function of different receptors, transporters, 
enzymes and ion channels associated with the membrane while SFAs are preferentially 
located at sn-1 positions (30). 
The AA, EPA and DHA are also classified as highly unsaturated fat acids (HUFAs) 
which perform several essential functions in the body. EPA and AA are FAs of the 
families n-3 and n-6, respectively. EPA and AA can be released from PLs by the action 
of phospholipase A2, and metabolized by cyclooxygenase (COX), lipoxygenase (LOX) 
and cytochrome P450 enzymes in different eicosanoids. COX metabolism leads to 
formation of prostaglandins and thromboxanes, while LOX leads the formation of 
leukotrienes and CYP 450 hydroxyl or epoxide the double bonds to form hydroxy- and 
epoxy PUFAs. These are important mediators of the inflammatory process (28). 
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Trans FAs (TFAs) are a group of unsaturated FAs with unique shapes and 
properties. Humans do not synthesize trans-FAs, they are obtained from the diet.  
Although naturally occurring trans-fat exists (ex. Conjugated linoleic acid), the main 
source of this type of FAs is dietary intake of industrialized products containing partially 
hydrogenated oils (31). These acids are originated from the cis isomers, that are modified 
during the chemical process (32).TFAs of the same length and weight as the original cis 
FAs, still have the same number of carbons, hydrogens, and oxygens but they are now 
shaped in a more linear form. This process converts oily bodies into semiliquid or solid 
fats for subsequent use in food products and the result of incorporation of hydrogen is a 
product with more oxidative stability (33). 
 
 
3.2. Phospholipids 
 
PLs are amphipathic molecules that consist of a hydrophilic head of phosphate 
and a hydrophobic tail composed by FA chains, thus tending to form lipid bi-layers. In 
fact, they are the main constituents of all biological membranes and allow establishing 
the organized structure of the membrane. These lipids confer a relatively rigid structure 
to the membrane, which confers protection and resistance to the cells. The PLs of 
membrane gives support for proteins, channels and other lipids, allowing exchanges 
between the internal and external environment. In addition to components of the 
membrane, PLs are also involved in other functions specially as signaling molecules (24). 
The metabolites resulting from the biosynthesis and degradation of PL are extremely 
important to the intracellular signaling and may be involved in processes of proliferation 
and apoptosis. 
There are two main classes of PL, one that has a glycerol backbone and other that 
contains sphingosine. PLs that contain glycerol backbone are called glycerophospholipids 
(GPs). The GPs are the major components of the membranes, and some have intrinsic 
biological activity acting as a second messengers. Structurally, these consist of a glycerol 
backbone linked by ester linkages to two FA chains in the positions sn-1 and sn-2, which 
may have similar or different characteristics (saturated, monounsaturated or 
polyunsaturated). In sn-3 position of the glycerol is esterified to a molecule of phosphate, 
which can bind, by phosphodiester linkage, to a polar molecule forming the PL polar head 
(24). Depending on the molecule which binds to the phosphate, different classes of GP 
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may occur: phosphatidic acid (PA), phosphatidylcholine or lecitin (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), 
Phosphatidylinositol (PI) (Figure 6) (24,34) . 
 
 
 
Figure 6. General structure of GP. R1 and R2 represent the fatty acyl chains esterified 
to glycerol backbone. Adapted from http://www.expertsmind.com/topic/membrane-
lipids/glycerophospholipids-94413.aspx 
 
 
Diphosphatidylglycerol or Cardiolipin (CL) is a dimeric PL with two phosphatidic 
acids linked by a central glycerol group. This group holds two more molecules of glycerol 
in its structure, and has four fatty acyl chains (Figure 7). The fact that the head group 
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alcohol is shared by two phosphates is a feature with important implications in CL 
mobility and conformational flexibility (35). 
 
Figure 7. The general structure of cardiolipin, R1 and R2 represent the fatty acyl 
chains esterified to glycerol backbone. Adapted from 
http://www.expertsmind.com/topic/membrane-lipids/glycerophospholipids-94413.aspx 
 
PLs can also be found in the membrane of organelles and where they are 
synthesized. PC, PI, PS and some PE are synthesized in the endoplasmatic reticulum 
while SM and some PC are synthesized in Golgi complex and CL and PE and are mainly 
synthesized in mitochondria (36). 
Lysophospholipids are any derivative of a PL in which one or 
both acyl derivatives have been removed by hydrolysis and these could be: 
Lysophosphatidylcholine (LPC), Lysophosphosphatidic acid (LPA), 
Lysophosphatidyletanolamine (LPE), Lysophosphatidylinositol (LPI), 
Lysophosphatidylglycerol (LPG) and Lysophosphatidylserine (LPS) (35). 
Lysophospholipids act as extracellular mediators activating specific G-protein-coupled 
receptors (GPCRs) and some of them additionally play a role in intracellular signal 
transduction (37).The several types of PLs have influence on many proprieties of cellular 
membrane and the main properties affected will be discussed in the next subtopic. 
PL that contain sphingosine backbone are called phosphosphingolipids. They 
have the same type of polar substituents as GP, mainly with choline polar head, differing 
only in hydrophobic group, which in this case is the ceramide, a molecule formed by the 
union of two FAs to a serine (which replaces the glycerol present in GP). The 
phosphosphingolipids more abundant in cell membranes are the sphingomyelin that is 
composed by a ceramide linked to phosphorylcholine polar head-group (Figure 8).  
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Figure 8. The general structure of Sphingomyelin. Adapted from 
http://en.wikipedia.org/wiki/File:Sphingolipids_general_structures.png 
 
SMs and the glycosphingolipids (composed by ceramide linked to a sugar polar 
head) contribute to the formation of membrane microdomains (also termed lipid rafts) 
based on their interaction with CHL. Lipid rafts are regions of membranes with a distinct, 
characteristic structural composition and that appear to act as signaling platforms by 
bringing together various signaling components involved in intracellular signaling 
pathways, facilitating their interaction. The PLs present in these rafts regions are usually 
highly enriched in saturated FAs compared with the surrounding non-raft regions of the 
membrane. They allow a closer packing of lipids within rafts because the sphingolipids 
also contain saturated FA side chains, and CHL and saturated FAs are able to pack 
closely. Because these lipid rafts are less fluid and more organized than the surrounding 
membrane, many proteins involved in signal transduction are predominantly found in 
these domains. Furthermore, these liquid rafts appear to act as signaling platforms by 
bringing together various signaling components, facilitating their interaction (38). 
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3.2.1. Influence of the phospholipids structures on the membrane properties 
 
 PLs comprise the most abundant class of membrane lipids and they have 
fundamental significance for a large number of biological proprieties of membranes like 
fluidity, permeability, asymmetry and curvature. The membrane is a fluid structure, 
meaning that the components do not occupy definite positions and are susceptible to 
displacement or rotation dimensional translation. This fluidity depends essentially on the 
composition of PL bilayer and also on the presence of CHL. The size of the alkyl chains 
is crucial in the fluidity of biological membranes, since the greater the alkyl chains of the 
PL, the greater the interaction between them, making the membrane less fluid. Another 
important factor is the degree of unsaturation of those chains. A higher proportion of 
unsaturated bonds in the alkyl chain, will result in the increase of the distance between 
adjacent chains, an area associated with weaker interactions, and as a result the membrane 
becomes more fluid (39). Another determining factor in the fluidity of membranes is 
CHL. The CHL molecules are interspersed with PL in the membrane, thereby decreasing 
the interaction between alkyl chains. Therefore, CHL affects membrane fluidity 
preventing perfect packing between the long chain hydrocarbon. The membrane fluidity 
affects the cell’s most essential functions, since it affects the rate of transport by 
transmembrane proteins and affects membrane permeability. The more fluid the 
membrane is, the more it becomes permeable to water and small hydrophilic molecules, 
and the greater the lateral diffusion of integral proteins (39,40). 
Biological membranes, are characterized by a typical transversal asymmetry, 
maintained by  differences in the lipid composition between the two leaflets with the 
exception of endoplasmic reticulum, where the lipids are transversal symmetrically 
distributed within the bi-layer (24).The aminophospholipids, PS and PE, are found 
primarily in the inner leaflet of the membrane, as well as PI and PA (less abundant lipids). 
Whereas the outer leaflet comprises the majority of lipids that contain choline, such PC 
and SM (35,41). The fact that the distribution of lipids in the bilayer is not homogenous, 
plays an important role in several functions such as maintain biophysical properties of 
specific membranes, facilitate membrane vesicle trafficking/fusion/budding and regulate 
activities of membrane proteins. An alteration of this PL asymmetry can also play an 
important role in activating cellular or biological processes like cytokinesis, blood 
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coagulation, cell fusion and recognition and removal of apoptotic cells (e.g 
externalization of PS by a cell) (24). 
Each type of PL possesses the so called spontaneous curvature, which originates 
due the size of FA chains relative to the head group that defines the molecular shape of 
PL, which can influence the curvature of a membrane. In cases in which the molecule has 
a cylindrical shape, such as, PC and PS the curvature is not induced. Lipids with a small 
head group compared with the hydrophobic part, like PE, are cone-shaped while lipids 
with a hydrophobic part smaller than the headgroup, like LPC, has the shape of an 
inverted cone (24) (Figure 9). Both have influence in curvature and since the lipid 
compositions of the membrane leaflets are different, the whole bilayer may develop a 
curvature. These differences might have a physiological role in the generation of 
curvature, for example, during vesicle budding, and during membrane fusion (24,42). 
 
 
Figure 9. The molecular shape of PL depends on the relative size of its polar 
headgroup and apolar tails. Since the lipid compositions of the membrane leaflets are 
different it will influence the curvature of membranes. Abbreviations: PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; LPC, lysophosphatidylcholine. 
Adapted from (42). 
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The selective permeability is another fundamental property of biomembranes 
influenced by the bilayer of PL. The semi-permeability is mainly due to the chemical 
nature of the biomembrane as well as the size and chemical nature of the substance which 
intends to charge through the membrane (43). Due to their hydrophobic nature of the 
hydrocarbon chains in lipid bilayers, they organize a virtually impenetrable barrier to the 
transport of ionic and polar substances. Specific membrane proteins regulate the 
movement of these substances into and out of cells. 
 
 
3.2.2. Influence of PL on cell signaling 
 
 GP and sphingolipids also play an important role in signal transduction either by 
binding and/or activation of signal transduction molecules and as substrates of lipases, 
lipid kinases and phosphatases (44). Three kinds of enzymes, phospholipases, lipid 
kinases, and lipid phosphatases, produce most lipid-derived second messengers and three 
membrane lipids are the primary sources of these signaling molecules: 
phosphatidylcholine, phosphatidylinositol and its various phosphorylated derivatives, and 
sphingomyelin (45). These three types of PLs can be degraded by phospholipases to form 
molecules important for the signal transduction. 
 Phosphatidylcholine (PC) is the major membrane PL in eukaryotic cells and  
beyond that PC serves as a reservoir for several lipid messengers: it is the source of the 
bioactive lipids LPC, PA, diacylglycerol (DAG), LPA, platelet activating factor (PAF) 
and AA (28). The generation of these lipid messengers from PC depends on their 
metabolism. PC can be cleaved by three phospholipases: Phospholipase C (PLC) that 
cleaves the phosphorylated head group from PC and it leaves behind DAG in the 
membrane bilayer; Phospholipase D (PLD) that cleaves the polar head group from 
glycerophospholipid, producing phosphatidic acid that remains in the bilayer and 
releasing the soluble choline headgroup into the cytosol; phospholipase A2 (PLA2) that 
removes the sn2 FA, giving a free FA, released into the cytoplasm, and a 
lysophosphatidylcholine (LPC) (Figure 10) (28,45). 
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Figure 10. Cleavage products of the action of phospholipases on PLs. The specific 
parent PL shown here is phosphatidylcholine. R1 and R2, FAs; DAGK, DAG kinase; 
PAP, phosphatidic acid phosphohydrolase. Adapted from (45). 
 
 
The phosphatidylinositol and its various phosphorylated derivatives are obtained 
by the addition of  phosphate groups to phosphatidylinositol  (by Lipid kinases) to make 
a variety of polyphosphoinositides, including phosphatidylinositol 4-phosphate (PIP), 
phosphatidylinositol 4,5-bisphosphate (PIP2), and phosphatidylinositol 3,4,5-
trisphosphate (PIP3) (Figure 11) (46). DAG and IP3 are important signaling molecules 
produced by a family of phosphoinositide-specific phospholipase Cs, and their substrate 
is PIP2 (28). DAG and phosphatidylinositol phosphate (PIP), are involved in calcium-
mediated activation of protein kinase C and PI3K-AKT survival pathway. The lipid 
phosphatases can remove a phosphate from phosphatidic acid (another way to make 
DAG) and phosphates from inositol head groups (24,45). 
Sequential action of two or more enzymes produces several other lipid second 
messengers. For example, cells can make DAG in two steps from phosphatidylcholine: 
PLD first makes phosphatidic acid (PA), and then PA is dephosphorylated to form DAG 
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by phosphatidic acid phosphatase (Figure 11) (28). Another example, is the action of PLD 
followed by PLA2 to yield lysophosphatidic acid (LPA) from phosphatidylcholine. LPA 
is a PL mediator with multiple biological functions such as, induction of cell proliferation, 
promotion of cellular tension and cell-surface fibronectin binding, and autocrine 
stimulation of platelet aggregation (47). When it is produced it escapes from cells and 
stimulate target cells by binding to G protein coupled receptors (GPCRs) and cells can 
respond to LPA in different ways: Activation of the PLC/IP3 pathway releasing the 
intracellular Ca2+ in some cells; activation of a mitogen-activated protein (MAP) kinase 
pathway stimulates cells division in some cases; and activation of Rho-family small 
GTPases stimulates formation of actin bundles in cultured cells. Platelet-activating factor 
(PAF), a modified PL also derived from PC, is formed by the cleavage of one FA from 
PC by PLA2 to yield LPC that by the action of an acetyltransferase is acetylated to yield 
PAF.  PAF binds to the GPCRs that stimulate PLC to generate the two second messengers, 
IP3 and DAG. These seconds messengers activate the PKC that can stimulates cell growth 
(45). 
 
Figure 11. The interrelatedness and interconvertibility of the lipid signaling 
pathways. PLA2, phospholipase A2; PLC, phospholipase C; PLD, phospholipase D; LPC, 
lysophosphatidylcholine; COX, cyclooxygenase; LOX, lipoxygenase; CYP2C, 
cytochrome P-450 2C; HETE, hydroxyeicosatetraenoic acid; HPETE, 
hydroxyperoxyeicosatetraenoic acid; EETs, eicosatrienoic acids; PAF, platelet-activating 
factor; PA, phosphatidic acid; DAG, diacylglycerol; IP3, inositol (1,4,5)-trisphosphate; 
PI(4)P, phosphatidylinositol (4)-phosphate; PI(4,5)P2, phosphatidylinositol (4,5)-
bisphosphate; PI(3,4,5)P3, phosphatidylinositol (3,4,5)-trisphosphate; PI-5-K, 
phosphatidylinositol 5-kinase; PI-3-K, phosphatidylinositol 3-kinase; C1P, ceramide- 1-
phosphate; S1P, sphingosine-1-phosphate; SPC, sphingosylphosphorylcholine. Adapted 
from (45) 
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Sphingomyelin can originate the sphingosine and sphingosine-1-phosphate (S1P) by 
a succession of enzymatic reactions (48). Ceramidase removes the FA, and 
sphingomyelinase removes the phosphorylcholine head group to form sphingosine. Then 
sphingosine kinase adds phosphate to C1 to make sphingosine-1-phosphate (Figure 12). 
Growth factor signaling pathways might regulate this lipid kinase. S1P escapes from cells 
and transmits signals through a family of G-protein-coupled receptors. Cells respond by 
releasing Ca2+, which influences motility and growth, as well as smooth muscle 
contraction (37,49).  
 
 
 
Figure 12. Structures released from sphingomyelin by enzymatic cleavage. Adapted 
from (45). 
 
 Several important cellular processes like cell proliferation, metabolism apoptosis 
and migration are controlled by signaling lipids such as phosphoinositides, eicosanoids, 
sphingomyelin and FAs. Enzymes that modify this lipids like phospholipases, 
phosphoinositide-3-kinase, COX, LOX, sphingosine kinase and sphingomyelinase are 
controlled by extracellular signals from growth factors, cytokines and nutrients. These 
enzymes and their targets constitute a complex lipid signaling network and imbalances in 
this network seems to contribute to the pathogenesis of human diseases such as breast 
cancer (44). 
 
4. Changes in lipid profiling and breast cancer 
Lipids are nowadays recognized as metabolites that have a key role in the 
development of several diseases and cancer is no exception. In addition, the lipid 
composition might vary with the diet that contains different types of FAs and many 
studies have tried to determine whether SFA, MUFA and PUFA have different effects in 
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the development and progression of breast cancer. Studies with cell culture have found 
that SFA (50), MUFA, TFA (32) and n-6 PUFA promote BC cell growth (51,52), whereas 
ALA, EPA and DHA inhibit BC cell growth (52). An exception within the MUFA class 
is oleic acid (18:1n9), which has been observed to have  anti-tumorigenic effects by 
suppressing overexpression of HER  (52,53).  
In animal studies, SFA and n-6 PUFAs, have a strong mammary tumor-enhancing 
effect (54,55) . In human studies of SFA and n-6 PUFA, the results are contradictory and 
it is not possible to reach a conclusion. At the same time, many studies support a role for 
n-3 PUFA in the prevention or inhibition of breast cancer. n-3 PUFAs can have 
chemopreventive and chemosuppressive properties against breast cancer and can be 
auxiliary agents for cancer therapy (56–58). Studies in human populations are limited, 
some have pointed out that high consumption of n-3 PUFAs is related to a reduced risk 
of breast cancer. Moreover, other studies failed to find a significant association. However, 
a large body of research involving animal and cell culture models supports a role for the 
long-chain n-3 PUFA (EPA and DHA) in the inhibition of tumor growth. Studies suggest 
that n-3 PUFAs induce modifications of membrane structure and function of breast cancer 
cells by increasing the degree of unsaturation of PLs (58). Thus, epidemiological evidence 
combined with the demonstrated effects of n-3 PUFAs on cancer in animal and cell 
culture models, has motivated the development of clinical interventions using n-3 PUFAs 
in the prevention and treatment of cancer. 
So, while most of the results obtained with DHA and EPA show a decrease of tumor 
cell proliferation and/or aggressiveness, there is some evidence that AA may have 
opposite effects. It is thought that having a high amount of n-6 PUFAs and a low amount 
of n-3 PUFAs in the diet, results in a high n-6/n-3 ratio and contributes for breast cancer. 
This shows that the ratio of n-6 to -3 may be more important than the absolute amount of 
n-3 PUFAs, as suggested by animal and human studies (59–61). So it seems that the 
development of dietary strategies that will result in an increase of n-3 in the diet, blood 
and tissues, associated with decreased omega-6, might have a beneficial effect in the 
health. 
Given all the results presented, it is clear that there is a very likely association 
between the dietary FA and breast cancer.  
Lipid rafts are known to be rich in signaling molecules and to regulate signal 
transduction in normal and cancer cells. Enrichment of lipid rafts with n - 3 PUFA are 
able to modify lipid raft biochemical and biophysical features. This will lead to the 
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decrease of breast cancer cell proliferation, probably through different mechanisms 
related to acyl chain length and unsaturation. FA are incorporated in breast cancer lipid 
rafts with different specificity for the PLs, in particular PUFA are incorporated in PS, PI 
and PC. While EPA may contribute to cell apoptosis mainly through decrease of AA 
concentration in lipid raft PLs, DHA may change the biophysical properties of lipid rafts 
leading to a redistribution of key proteins (38,62). 
Diverse evidences of the probable mechanisms regarding how PUFA may modify 
the carcinogenic process, have been proposed. FAs intake by the cell, regulates lipid 
metabolism, including FA elongation and desaturation. Thereafter, FAs are esterified to 
glycerol and enter the PL biosynthetic pathway. Therefore, the kind of FA in the diet may 
influence the PLs of the cell membrane and thus affect cell properties and function. A 
high content of PUFA makes the cell membrane more fluid, which will result in 
alterations of membrane fluidity that can seriously affect functional properties of the cell 
and induction of apoptotic pathways, resulting in cell death (58,63). Another mechanism 
by which the fatty diet can interfere in the process of carcinogenesis is by lipid 
peroxidation. PUFAs are susceptible to lipid peroxidation and as such, PUFA in the diet 
can result either in an increased consumption of oxidized FAs, or promote lipid 
peroxidation in the body. The metabolites of this reaction are extremely toxic and may 
promote carcinogenesis through stimulation of cell proliferation. Also the dietary FAs 
and their metabolites may affect the activity of transcription factors, gene expression and 
signal transduction, mechanisms that generate changes in proliferation or apoptosis (64).  
Finally, the proportion of PUFA in the cell membrane is one of the main factors 
that will determine the class of eicosanoids that will be synthesized (28). Eicosanoids are 
biologically active substances derived from essential FA that act in the body by 
modulating the inflammatory activity and immune response, and are involved in platelet 
aggregation, cell growth and differentiation (28,64,65). Further studies are needed to 
evaluate and verify these mechanisms in humans to have a better understanding regarding 
the effects of PUFA intake on cancer risk/ development. 
FAs are not the only lipids connected to breast cancer physiopathology (66). As 
mentioned above, PLs are also involved in signal transduction and are thought to be 
involved in cancer. It is known that alterations in PLs are found in breast cancer cells and 
these alterations can change the normal function of the cell (66,67). Some studies showed 
high levels of PC and PE were detected in breast cancer cells and contain considerably 
greater amounts of unsaturated FAs when compared to normal breast tissue (68). 
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However a recent study by Doria et al that described the differences and similarities 
between mammary epithelial and breast cancer cells, and between breast cancer cells with 
different levels of aggressiveness found different changes. The most abundant PL class 
in all cell lines was PC, followed by PE. Increased relative amounts of LPCs were found 
in more aggressive, indicating that alterations in these PLs could be associated to 
malignant progression. Also changes in PE profile also were found, PE relative levels 
were highest in non-malignant cells (67).  
PIs and  their metabolites such as phosphatidic acid (PA) and DAG, and 
phosphorylated derivatives of PI, phosphoinositides (PIP), are very important 
contributors to cellular signaling cascades that activate proliferation, maintain survival 
and promote migration (69). Imbalances in their relative levels lead to changes in cellular 
functions that may contribute to the onset of cancer (70).  
S1P is a signaling molecule that has the ability to act as an intracellular second 
messenger, as well as an extracellular stimulus through specific G protein-coupled 
receptor (GPCRs) (48).  S1P regulates many processes important for the normal cell 
physiology  (46,71). Alterations in S1P signaling, as well as in the enzymes involved in 
its synthesis and metabolism, have been observed in many types of pathological 
conditions including in breast cancer (72). LPA, is a lysophospholipid which has some 
structural similarities to S1P, performing many of its extracellular effects acting in 
specific G-protein-coupled receptors (46). These interactions are important for the cell 
proliferation, migration and survival. Therefore deregulation of LPA production, receptor 
expression or signaling will probably contribute to cancer initiation, progression and 
metastasis (37). 
The Lipids reported above have an essential role in normal function of the cell. 
Changes in lipidome of cells can lead to imbalances in biological properties of membranes 
and on signaling that can lead to onset and development of cancer. It is known that 
different dietary FA have different effects, however little is known about their impact in 
lipidome of breast cancer cells and their association with cell growth, viability and 
apoptosis. Thus, the role of different dietary FAs in the profile of PLs of cells of breast 
cancer is not completely understood and remains controversial, being necessary more 
studies to reach more conclusions.   
 
 
 
 27 
 
5. Lipidomics approach on breast cancer 
 
Lipidomic is considered a branch of metabolomics that studies the lipidome, i.e., 
the total lipid composition of a cell or organ, and their interactions with other lipids, 
proteins and other molecules present in biological samples in their natural environment. 
Lipidomics have been subject of a great development in the last decade (73). 
There are several experimental approaches that could be used in lipid research, such 
as chromatography, mass spectrometry, nuclear magnetic resonance (NMR). NMR could 
be used to analyze lipids directly in a nondestructive manner, however, the sensitivity of 
NMR is low and allows to identify the more abundant and dominant lipids (such as CHL 
and PC). Having this into consideration, the most used techniques nowadays are 
chromatography and mass spectrometry (74). 
Lipidomics usually involves several steps. First is necessary the extraction of lipid 
from tissues or cells. Almost all lipid extraction methods use organic solvents to take 
advantage of the high solubility of lipids in organic solvents, i.e., lipid separation is 
created between immiscible solvents because lipids go into a hydrophobic phase. Then, 
to separate class of PLs it is used chromatography methods, and the most popular and 
simple is thin-layer chromatography (TLC), this facilitates further analysis and 
identification of lipids, already divided by their families. The components of the sample 
will be separated based on their varying physical and chemical properties, imparting 
different affinities for the two phases allowing the separation and identification of 
different PL classes be comparison to the standards also applied on the TLC plate (75). 
PL content of each class can be measured by phosphorous assay that measures the 
inorganic phosphate present in the lipid sample.  
To study FA profiling, mass spectrometry coupled to gas chromatography (GC-
MS). Mass spectrometry is a technique that performs the molecular identification through 
determining the ratio of mass to charge (m/z) of a molecular (74,76,77). A mass 
spectrometer typically is constituted by four principal components: a system to introduce 
the sample into the source of ionization; the ionization source, where the analyte 
molecules enter the instrument and are transformed into gaseous ions; the mass analyzer 
that separates the ions according to their mass-to-charge ratio (m/z); and the detector in 
which the separated ions are collected and characterized by the production of a signal 
whose intensity is related to the number of detected ions (78). 
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With the rapid development of lipidomics techniques, more attention has been paid 
to lipids because of their important roles in tumor diagnosis and therapy. MS has played 
an essential role in the study of PL and fatty acids in cancer cells, because it is a technique 
that combines speed, specificity, selectivity and sensitivity (67,74). It is known that a 
lipidomic approach is useful to define differences among PL classes and their molecular 
species. However, until this moment information about lipidome changes in cancer 
progression is rare, because in general these studies are only centered on one or few PL 
classes. Therefore, it is necessary to carry out more studies to provide more information 
(79,80).  
Studies of effect of different dietary FAs on lipidome of cancer cells are scarce. 
Understand the role of dietary FAs in the profile of lipids of breast cancer cells and 
correlate it with cell proliferation and apoptosis is very important to prevention, and 
because it could provide new therapeutic opportunities and biomarkers for breast cancer 
that could modulate the progression of breast cancer. 
 
6. Aim of the study 
 
The role of different dietary FA in breast cancer cell growth is not completely 
understood and remains controversial. Further, the relationship between cell proliferation, 
death and how these processes are related to changes in the cellular lipid profile remains 
unknown. Thus, lipidomic studies are needed to better understand these issues. 
 
The aim of this work was to establish how the lipidome of a breast cancer cell line 
differs with exposure to dietary FAs and correlate these findings to the effects in 
proliferation and apoptosis. For this purpose, the breast cancer cell line T47-D was 
cultured with oleic acid (C18:1n-9) or linoleic acid (C18:2-n6) for 6 days, following 
which viability, apoptosis, TG and CHL content, PL classes and FA changes were 
analyzed. 
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II. Methodology 
 
1. Chemicals 
PE, PS, PC, PI, SM, LPC and CL standards  (Avanti Polar Lipids), triethylamine  
(Acros Organics), chloroform and n-hexane  (VWR Chemicals HPLC grade),  methanol  
(Fisher Chemical HPLC grade),  ethanol  (Panreac), primuline (Sigma-aldrich), Mili-Q 
water (Millipore Synergy), methyl-tert-Butyl ether (MTBE) (VWR Chemicals HPLC 
grade), ammonium  molibdate de amónio (Panreac), quantification standard of PL 
(Riedel-deHaen), acetone (Sigma-aldrich HPLC grade), boric acid (BDH Chemicals), 
percloric acid 70% (Chemlabs HPLC grade), sodium chloride (NaCL) (Absolve),  
potassium hydroxide (KOH) (EKA Chemicals), TLC silica gel 60 plates with 
concentration zone (2.5x20cm) were purchased from Merck (Darmstadt, Germany), FBS 
(PPA, Austria), Trypsin-EDTA, PEST and PrestoBlue™ reagent (Invitrogen, Life 
Technologies, USA). Insulin, Triton X-100 and DMSO (Sigma, USA). For protein 
quantification it was used the DC protein kit (BioRad, Hercules, CA) and for TG and 
CHL quantification it was used a LiquickCor-TG and LiquickCor-CHL kit (Cormay, 
Poland), respectively. Finally for apoptosis assay it was used CellEvent Caspase-3/7 
Green Detection Reagent (Invitrogen, Life Technologies, USA). 
 
2. Cell culture 
T47-D cells were grown in RPMI-1640 medium plus PEST and 10% FBS. For 
lipidomic and immunoblot experiments cells were seeded in 10 cm-diameter dishes and 
for cell survival, apoptosis and cell counting experiments 1000 cells / well were seeded 
in 96-well plates. Twenty-four h later, medium was changed to RPMI-16040 + PEST + 
2% FBS + 5 ug/ml insulin with addition of OA or LA dissolved in DMSO or same volume 
of control DMSO alone. Control group received same volume of DMSO (final 
dilution1/500). 
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3. Cell viability 
T-47D cell viability was measured using PrestoBlue™ reagent. Briefly, the cells 
treated with the FAs were incubated with the reagent directly added to the cells in culture 
medium diluted 100x. Then, cells were incubated for 240 minutes at 37º C and the 
absorbance was measured at 570 nm and 600 nm, every half hour, using a microplate 
reader (Multiscan 90, ThermoScientific). The percent reduction of PrestoBlue reagent 
were calculated from the absorbance data by using the following 
equation:
(𝑶𝟐 ×𝑨𝟏)−(𝑶𝟏 ×𝑨𝟐)
(𝑹𝟏 ×𝑵𝟐)−(𝑹𝟐 ×𝑵𝟏)
× 100, where: O1=molar extinction coefficient of oxidized 
PrestoBlue reagent at 570 nm (80586), O2=molar extinction coefficient of oxidized 
PrestoBlue reagent at 600 nm (117216 ), R1= molar extinction coefficient of reduced 
PrestoBlue reagent at 570 nm (155677), R2= molar extinction coefficient of reduced 
PrestoBlue reagent at 600 nm(14652), A1=absorbance of test wells at 570 nm, 
A2=absorbance of test wells at 600 nm, N1=absorbance of media only wells at 570 nm 
and N2=absorbance of media only wells at 600 nm. Two independent experiments were 
performed, using at least triplicates. 
 
4. Lipid extraction 
Following growth with the FAs for 6 days, cells were scrapped using a rubber 
scraper and re-suspended in 1 ml of PBS. From this solution, 100 µl were separated for 
protein quantification. The remaining 900 µl were used for lipid extraction with methyl-
tert-butyl ether (MTBE) based protocol for lipid extraction (81). Briefly, 1,5 ml of 
methanol was added to the cell pellet and the solution was vortexed. Then, 5 ml of MTBE 
was added and the mixture was incubated for 1 h at room temperature. Separation of 
phases was achieved by adding 1.25 ml of mili-Q H2O water. After 10 min of incubation 
at room temperature, the sample was centrifuged at 1500 rpm for 10 min. The upper phase 
(organic) was collected, and the lower phase was re-extracted with 2 ml of 
MTBE/methanol/water (10:3:2.5, v/v/v). Both organic phases were dried in a speed 
vacuum centrifuge. Extracted lipids were dissolved in chloroform and then dried under 
nitrogen flow for storage at -20ºC. 
 
 33 
 
5. PL quantification 
To quantify the total amount of PLs as well as amounts of each PL class separated  
by TLC,  a  phosphorus  assay  was  performed  according  to  Bartlett  and  Lewis (82). 
Briefly, 0.65mL of percloric acid 70% were added to the samples which were then 
incubated in a heating block, 1 hour at 200°C. Standards were prepared by the addition 
of 0.65mL of percloric acid 70% to aliquots with 0.1 to 2 µg of phosphate. To all samples 
and standards, we added 3.3 mL of H2O, 0.5 mL of ammonium molibdate (2.5 g 
ammonium molibdate/100 mL  of  H2O)  and  0.5  mL  of  ascorbic  acid solution (10  g  
ascorbic  acid/100  mL  of  H2O),  and vortexed after the addition of each solution, 
following by the incubation in a bath at 100ºC, 5 min. The absorbance was measured at 
800 nm, in a microplate reader (Multiscan 90, ThermoScientific). In the case of PLs 
separated by TLC, prior to spectrophotometric determination, the samples were 
centrifuged 5 min at 4000 rpm to separate PLs from silica. The phosphorous content in 
each spot was related to total phosphorous content in the sample. Three independent 
experiments were performed, using duplicates for each experiment. 
 
6. Thin layer chromatography 
PL classes from the total lipid extract were separated by thin TLC using silica gel 
plates with concentrating zone 2,5x20cm. Before the separation, the plates were washed 
in a solution of CHCl3: MeOH (1:1 v/v) and treated with a solution of boric acid in ethanol 
(2.3% w/v). Thereafter, the plate were dried in an oven at 100ºC during 15min and then  
20  µl of each total lipid extract   re-suspended in chloroform and containing about 30 µg 
of total PL (in a concentration  of  150  µg  of PL per  100  µl) were applied in the plates. 
The plates were developed with a mixture of solvents CHCl3: MeOH: H2O: triethylamine 
(30:35:7:35, v/v/v/v). To visualize the PL spots after elution, the TLC plates were stained 
with a primuline solution (50 µg/100 mL   acetone: water 80:20, v/v) and visualized with 
a UV lamp (λ=254nm). After  the  identification  of  the  PL spots,  by  comparison  with  
PL standards, the spots were  scraped to  quantify amount  of phosphorus  with a 
phosphorus  assay to calculate the percentage of each PL class in the total amount of PL 
in the sample. Three independent experiments were performed, using duplicates for each 
experiment. 
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7. Protein quantification by DC assay 
For protein quantification we used the DC protein kit. We added 20 µL of S reagent 
from the kit to 1mL of reagent A (alkaline cooper tartrate reagent), to form reagent A'. 
Standards of BSA 0.2 mg/mL to 1.5 mg/mL were also prepared. Then, 5 µL of each 
standard and each sample were mixed with 25 µL of reagent A' and 200 µL of reagent B 
(a dilute Folin Reagent), and incubated at room temperature for 15min. The absorbance 
of all the samples was measured at 750 nm using a microplate reader (Multiscan 90, 
ThermoScientific). Three independent experiments were performed, using duplicates for 
each experiment. Protein concentration was used to normalize the data and compare the 
amount of TGs, CHL and total PL between the treatments. 
 
8. Gas chromatography coupled with mass spectrometry 
To analyze the FAs present in total lipid extract we used GC-MS. We used 20µL 
of each total lipid extract, containing about 30 ug of total PL, and dried it with a nitrogen 
flow. The sample were re-suspended with 1mL of hexane and then mixed with 200µL of 
KOH (2M). As the next step, 2 mL of NaCl were added and the mixture was then 
centrifuged at 2000 rpm during 5 minutes. The upper phase was transferred to another 
tube and the solvent was evaporated under a nitrogen flow. Finally, the sample was re-
suspended on 60 µL of n-Hexane, and 2 µL of this solution was injected in a gas 
chromatography-mass spectrometry (GC-MS). The GC was an Agilent Technologies 
6890N Network (Santa Clara, CA) equipped with a DB-1 column with 30 m of length, 
0.25 mm of internal diameter, and 0.1 µm of film thickness (J&W Scientific, Folsom, 
CA) and was connected to an Agilent 5973 Network Mass Selective Detector operating 
with an electron impact mode at 70 eV and scanning the range m/z 40-500 in a 1 s cycle 
in a full scan mode acquisition. The oven temperature was programmed from an initial 
temperature of 40 ºC, standing at this temperature for 0.5 min, a linear increase to 220 ºC 
at 20 ºC/min, followed by linear increase at 2ºC/min to 240ºC, and then at 5 ºC/min to 
250 ºC. The injector and detector temperatures were 220 and 230 °C, respectively. The 
gas used was Helium at a flow rate of 1.7 mL/min. Identification and analysis of peaks of 
the spectrum was carried out using a using software that came with the equipment 
(MSDA). The peaks were identified by the retention time and using a standard library. 
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Then the peaks were integrate to obtain an area. Each area was related to total area of the 
sample giving the % relative content of FAs. Three independent experiments were 
performed, using duplicates for each experiment. 
 
9. Total triglyceride and cholesterol 
Prior measurement, we prepared the samples to allow the formation of liposomes 
needed for the quantification using this type of colorimetric kit. For this, we used 20 µL 
of sample previously dried under nitrogen flow, which was re-suspended in 40 µL of 
ammonium hydrogen carbonate 5 mM pH 7.4 buffer with addition of 5 % of Triton X100. 
Then, the sample was sonicated for ten minutes to emulsify and used for TG and CHL 
quantification. Total TG quantification was carried out with the LiquickCor-TG kit. 
Briefly, for the working reagent preparation we mixed gently 4 parts of 1- TG with 1 part 
of 2-TG reagents. This solution (0.5 mL) was mixed with 5µL of each sample and the 
standard, and incubated at 37ºC, 5 min. At last, the absorbance of all the samples was 
measured at 500 nm using a microplate reader (Multiscan 90, ThermoScientific). For total 
CHL quantification we used the LiquickCor-CHOL kit. Briefly, 5µL of each sample and 
the standard were mixed with 0.5 mL of reagent, and incubated at 37ºC, 5 min. The 
absorbance of all the samples was measured at 550 nm using a microplate reader 
(Multiscan 90, ThermoScientific). Three independent experiments were performed, using 
duplicates for each experiment. 
 
10. Cell counting 
To count the cell number resulting from 6 days of treatment with the FAs, cells 
were detached with Trypsin-EDTA and counted in a TC 20 TM Automated cell counter 
(BioRad). All treatments were done with four replicates. 
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11. Apoptosis assay 
For detection of apoptosis we used the CellEvent Caspase-3/7 Green Detection 
Reagent which is a fluorogenic substrate for detection of activated caspases 3 and 7 in 
apoptotic cells. It was prepared by adding 1 drop of reagent in 500 uL of PBS and then 
100 uL of this solution was added to each sample followed by incubation for 1 hour at 
room temperature in the dark. To evaluate apoptosis it was used an inverted microscope 
(Niko TiU) using a 480 nm FITC filter. 
 
12. Statistical Analysis 
We analyzed three independent experiments (n=3). The results were presented as 
means ± standard deviation (SD) or standard error of mean (SEM) when more than one 
independent measurement was carried out for the same sample.  Differences between the 
groups were compared by one way analysis of variance (ANOVA) with the Dunnett’s 
post-hoc test. For comparison of two groups two-tailed t-test was used. Values of p<0.05 
were considered statically significant. Statistical analysis was carried out using PRISM 
GraphPad Software, Inc.  
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III. Results and discussion 
 
As one approach to understand the influence of dietary MUFAs and PUFAs on 
human breast cancer, we have studied the effects of OA and LA in vitro in cultured human 
breast cancer cell line, T-47D (belongs to the luminal A group, with low metastatic 
potential). We chose to use a concentration of 1ug/mL C18:1n9 (Oleic acid –OA), 
previously shown to exert antiproliferative effects (83); and concentrations of 1ug/mL 
C18:2 n-6 (linoleic acid - LA1) and 2ug/mL C18:2 n-6 (LA2), previously shown to be 
pro-proliferative (84).  
The lipid changes in lipidome induced by the presence of these FAs 
supplementation were study through a lipidomic analysis, based on techniques such as 
TLC and GC-MS. TLC allowed the separation of PL classes and GC –MS allowed the 
separation of FAs and their quantification. TGs and CHL were quantified by colorimetric 
methods. Cell viability and apoptosis were also evaluated. 
1. Cell viability 
On a first approach we did an assay of cell viability commonly used to evaluate cell 
metabolic activity (Figure 13).  
 
Figure 13. Effects of FAs supplementation on cell viability. Cell metabolic activity 
was determined using PrestoBlue assay for cells treated with different FAs and metabolic 
activity was measured every half hour until 240 minutes. Legend: Control – Without FA; 
OA1- Oleic acid (C18:1n9 1ug/mL); LA1- Linoleic acid (C18:2 n-6 1ug/mL); LA2- 
Linoleic acid (C18:2 n-6 2ug/mL). Statistical significance was measured with One-way 
ANOVA and Dunnett’s post-hoc test, **: p< 0.01 (LA1); ***p<0.001 (LA2) starting in 
180 min. 
 40 
 
 
This assay is based on detection of metabolic activity underlying resazurin 
reduction. Resazurin is a fluorescent redox indicator dye that is frequently used to 
determine viability of cells directly in culture, where only viable cells are able to convert 
the dark blue oxidized form of the dye (resazurin) into a red-fluorescent reduced form 
(resorufin). The results are expressed in % of reduction, so a biggest reduction is 
correlated to a greater total metabolic activity that is used quantitatively as a measure of 
cell growth and integrity. Thus, we can see that cells treated with LA1 (**: p<0.01) but 
especially with LA2 (***: p<0.001) showed increased reduction of resazurin into 
resorufin over time particularly since the 180 min. This indicates that a medium with LA 
increased stimulation of T47-D metabolic activity, being more effective in supporting cell 
growth than the treatment with OA that had approximately the same values of control.  
The results were consistent with literature, which showed that a range of 
concentration of LA had a stimulatory effect on the growth of T-47D cells, including 1 
and 2 ug/mL of LA. Only at concentrations exceeding 10 ug/mL was observed 
cytotoxicity in  breast cancer cells (84). 
 
To confirm the viability assay results, cells were counted and apoptosis was 
evaluated. For this new set of experiments, T-47D cell line was treated with the same FAs 
(OA1, LA1 and LA2) but this time, an additional condition has been added, a culture 
medium with (2ug / mL  OA) in order to see if the lack of variation in metabolic activity 
with OA was related to suboptimal OA concentrations. 
 
2. Cell counting 
Cell counting results are presented in Figure 14. 
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Figure 14. Cell number was measured by cell counting. The graph shows the number 
of cells per ml in control and treated with OA1, OA2, LA1 and LA2. Each value 
represents the average of four measurements. Statistical differences were analyzed with 
One-way ANOVA and Dunnett’s post-hoc test, but no differences were found. 
 
There was no statistically significant difference between the numbers of cells 
treated with these FAs. However, a clear tendency to increase cell number was observed 
for LA2 in relation to other treatments. In addition to this, we can see a slight decrease of 
cell number in the treatment with OA2. These results suggest that LA2 could enhance cell 
population growth and OA2 might have the opposite effect. 
 
3. Apoptosis assay 
To evaluate apoptosis, it was used the CellEvent Caspase-3/7 Green detection 
reagent, that is a new fluorogenic substrate for activated caspases 3 and 7, showing bright 
green nuclei when caspase 3/7 are activated. Therefore, this assay showed qualitatively 
which of the treatments promote a greater apoptosis. In Figure 15 the results of the assay 
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are shown and the treatment with OA2 is the one which resulted in more apoptosis 
comparatively to control.  
 
Figure 15. Apoptotic assay of T-47D cells treated with OA and LA in different 
concentrations. Apoptotic cells labelled with activated caspase 3/7 show bright green 
nuclei. Each image side by side correspond to different representative pictures taken of 
same treatment.  
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The information obtained in this assay is consistent with the cell counting, where a 
slight decrease in cell number in OA2 treatment was observed, although not statistically 
significant. LA2 did not show less evidence of apoptosis than the other treatments, but 
according to the assay of viability and cell counting this treatment stimulates growth. So 
this is probably due to stimulation of proliferation. 
 
4. Effect of FAs on total lipid content 
The total amount of lipid in each of the samples and the total cell protein content, 
were determined. The results are shown in Table 1. 
 
Table 1. Results of quantification of PL (ug) and protein, P (mg) per 900 uL of 
sample. R1, R2, R3 are the three independent experiments; each measurement was 
carried out in duplicate. Legend: Control – Without FAs; OA1- oleic acid (C18:1n9 1 
ug/mL); LA1- linoleic acid (C18:2 n-6 1 ug/mL); LA2- linoleic acid (C18:2 n-6 2 ug/mL); 
 
A large difference in the protein concentration was observed, and this is directly related 
to the cell number. Still, PL quantification also revealed differences between independent 
experiments.  So, to make sure that the variations of total PL levels were due to treatment 
with FAs, to which the cells were exposed, and not to differences in the number of cells 
Mean SD Mean SD Mean SD Mean SD
R1 1212,90 107,30 1172,00 59,59 1032,00 9,53 1385,90 129,24
R2 242,70 2,13 282,50 4,00 565,90 9,33 450,80 19,19
R3 1701,02 79,39 2176,86 61,81 2066,85 128,94 1988,11 3,73
Mean SD Mean SD Mean SD Mean SD
R1 536,31 3,17 487,64 6,79 477,07 39,85 710,81 92,37
R2 214,52 1,20 276,00 24,45 639,73 38,94 393,19 21,73
R3 1395,04 81,96 1743,72 28,07 1733,48 55,24 1590,36 123,23
Mean SD Mean SD Mean SD Mean SD
R1 8,48 0,66 10,38 0,00 9,37 2,53 9,35 0,24
R2 6,74 0,03 7,87 0,21 7,14 0,40 5,95 0,09
R3 10,19 0,56 9,77 0,95 10,31 0,11 9,66 0,19
Control OA1 LA1 LA2
P (mg)
Control OA1 LA1 LA2
PL (ug)
Control OA1 LA1 LA2
Reptetition of quantification
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of each independent experiment, the values of quantification were normalized to total cell 
protein content, the results are presented in Figure 16. 
Figure 16. Amount of lipid in each sample expressed by ug of PL per mg of protein. 
A, B, and C correspond to the first quantification of R1, R2 and R3; respectively; D, E 
and F correspond to the second quantification. Mean +/- SD from duplicates is shown. 
Note: the difference in the PL amount between A and D, which correspond to R1is due to 
the fact that in D, some sample had already been used for other purposes. 
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It is possible to see that the two quantifications gave similar results, showing that 
the difference observed between each independent experiment is not due to experimental 
error, but to variability between samples. To better visualize possible differences in total 
PL amount, the values were normalized relative to control (Figure 17). 
 
Figure 17. Graphic representation of the amount of PL in each sample expressed 
by ug PL / mg protein relative to control (mean +/- SD). 1, 2 and 3 correspond to 
values from R1, R2 and R3 of the two quantifications. Statistical differences were 
analyzed with One-way ANOVA and Dunnett’s post-hoc test, but no differences were 
found. 
 
Taking the results into account, differences in total PL content were not considered 
significantly different between the treatments.  
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5. Effect of dietary fatty acids on cellular fatty acid levels 
In order to see if exogenous FAs affect cellular FA levels, analysis of modification 
of FA profile (free and esterified) of the total lipid extract from T-47D cells supplemented 
with different FA treatment (Figure 18) was performed by using GC-MS methodology.  
 
 
Figure 18. GC-MS quantification of FAs in total lipid extract. The results are relative 
to total FAs and are presented as Mean +/- SD. 
 
Observing the results we can see that there are some alterations in the FA profile. 
The major difference is related to 18:2 n-6 in cells treated with LA1 (p<0.05) and LA2 
(p< 0.01), that showed an increase in the relative content (Figure19). This suggests that 
18:2 n-6 from the medium is being accumulated directly in lipids of cells but probably 
not metabolized into other FAs, namely 20:3 or 20:4n-6. 
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Figure 19. The relative content of 18:2 FA in T-47D cells. The results are presented as 
FA Mean +/- SD normalized relative to untreated control from three independent 
experiments. Statistical significance was measured with One-way ANOVA and Dunnett’s 
post-hoc test,*: p<0.05; **: p< 0.01 
 
To better analyze the FAs present in minor quantities, the results were normalized 
to the untreated control and plotted with a smaller scale. However, differences were not 
statistically significant (Figure 20). 
 
Figure 20. GC-MS quantification of minor FAs in total lipid extract from T-47D cell 
line. Mean +/- SD normalized relative to untreated control from three independent 
experiments. Statistical significance was measured with One-way ANOVA and Dunnett’s 
post-hoc test, but no differences was found. 
Treatment 
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LA can change the cell FAs composition, and may be stored as PLs. So if the 
accumulation of 18:2 n-6 occurs in the PLs, which are the major structural components 
of biological membranes, it will alter the ratio between saturated and unsaturated FAs. 
This effect will change the lipid composition of membrane, which may lead to variance 
in membrane fluidity, possibly leading to alterations on proteins of membrane like the 
conformation of certain transporters, receptors, and enzymes that are sensitive to changes 
in the structure of their lipid microenvironment, leading to changes in protein activity 
(84,85).Broadly, alterations in membrane fatty content change the membrane-receptor 
and cell-to-cell communications resulting in abnormal and unregulated cell function (85). 
FA also could be incorporated into storage lipids (TG and CHL esters), or directly 
oxidized to produce energy (86). Besides that, FA may also influence the function of the 
cell as free FA (FFA). In literature has been proposed the different mechanisms by which 
FFA can influence progression of cancer. For example, they can interact directly with 
enzymes or receptors and depending on their structure they can modulate their functions 
differently. Furthermore, they can acylate proteins and, which is important for anchoring 
certain proteins in membranes or for folding of the proteins, and it is crucial for the 
function of these proteins (86). For example, protein modification with SFA can promote 
their association with CHL of lipid rafts, whereas PUFA, like 18:2 n-6 exclude proteins 
from these structures leading to changes on the activity of signaling complexes that are 
associated with membrane rafts. Still, FFA and their derivatives (eicosanoids or acyl-
CoA) may interact with nuclear receptor proteins that bind to certain regulatory regions 
of DNA altering the transcription of genes (29,87).In a study with T-47D cells, the 
treatment with LA provided information that LA may influence cell cycle progression 
and global gene expression. They have found that treatment of T-47D cells with LA is 
associated with an up-regulation of oncogenes, modulation of growth factor signaling and 
regulation of the cell cycle machinery. These include genes involved in transcriptional 
regulation, cell cycle control, G protein and MAP kinase signaling pathways, supporting 
the data that linoleic acid increases T-47D cell proliferation (84).  
Therefore, the increase of cellular 18:2 n-6 in cells treated with LA1 and LA2 could 
be incorporated in PLs or to storage lipids (TG and CHL esters). Also the FFAs could be 
captured by cells and then activated to produce energy, to modulate enzymes or produce 
eicosanoids, or even to bind to transcription factors that regulate gene expression. 
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6. Total triglycerides quantification 
FAs can be used to generate many different types of lipids, for example they can be 
converted into TGs via the glycerol phosphate pathway (29). Therefore it is important to 
understand if the FAs supplemented in the medium could be stored as TG.  
The analysis of TGs was carried out using a colorimetric enzymatic method (Figure 
21). As we can see, the results were not reproducible, even in the control samples. These 
assays were originally devised to measure TG levels in human serum samples which 
travel in plasma in soluble lipoprotein complexes. Thus, the lipase used in the colorimetric 
assay kits can efficiently form free glycerol (the measured product) in these conditions. 
However, our sample is a total lipid extract (hence, it is very hydrophobic), so what could 
be happening is that the approach used for solubilization is not effective and the liposomes 
used to mimetize the lipoprotein, are not correctly formed. Moreover, we tried to optimize 
the method of quantifying the TG, by adding 5% Triton X100 to the ammonium hydrogen 
carbonate buffer to try to solubilize better the samples. Triton X100 has been used in other 
procedures with little evidence of loss of lipase enzyme activity (88).  
 
 
Figure 21. Quantification of TG in total lipid extract from cells treated with different 
FAs. TG values (mg/dL) were normalized to protein content and related to the untreated 
control. Mean +/- SD from three independent experiments t-test was used to analyze 
significant changes. 
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A pilot study, was carried out in an attempt to predict an appropriate sample dilution 
and to analyze if addition of 5% Triton X100 would improve the reproducibility of the 
assay (Figure 22). Since 5% of Triton X100 and greater dilution improved the assay, we 
proceeded to the measurement of TG in our samples (Figure 23). 
 
 
Figure 22. Pilot test to see which condition better solubilized the sample. The samples 
had a known concentration of TG (220 mg/dL). Legend: A1 – Ammonium hydrogen 
carbonate buffer 5 mM pH 7.4 dilution than 1/5; A2 – Ammonium hydrogen carbonate 
buffer 5 mM pH 7.4 with 5% Triton X100 at a dilution 1/5; B1 - Ammonia hydrogen 
carbonate buffer 5 mM pH 7.4 at a dilution 1/3; B2 – Ammonium hydrogen carbonate 
buffer 5 mM pH 7.4 with 5% Triton X100 at a dilution 1/3. Mean +/- SD is shown. 
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Figure 23. Quantification of TGs in total lipid extract from cells treated with 
different FAs. TG values (mg/dL) were normalized to protein content and related to the 
untreated control. Mean +/- SD from three independent experiments t-test was used to 
analyze significant changes. **: p<0.01. 
 
The results indicate that total TGs were decreased in cells treated with LA2 
compared with other conditions. Increased cancer cell proliferation requires the rapid 
synthesis of lipids for the generation of biological membranes (86,89). Since the culture 
medium used is a medium that only has essential nutrients for growth, was hypothesize 
that cells treated with LA2 that have increased metabolic activity and cellular 
proliferation might be using TGs to provide metabolic substrates for energy production 
(via FA oxidation) and membrane lipids, decreasing the levels of TGs total content. Also, 
TGs might be used to produce metabolites important for cell growth and proliferation 
(86). Thus, even though LA2 results in increased cellular 18:2 n-6 levels, it is possible 
that it does not accumulate as part of the TGs. 
 
 
 
 
Treatment 
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7. Total cholesterol quantification 
CHL is essential for the normal function of all animal cells. It is an important 
membrane component that modulates the fluidity of the lipid bilayer, especially in lipid 
rafts. CHL alterations affect lipid raft structure and also might alter the receptors function, 
so the levels of CHL is a key factor to determine lipid raft stability and organization (38). 
The analysis of CHL was carried out using a colorimetric enzymatic method. In this 
assay the CHL esters are hydrolyzed by CHL esterase to form free CHL, which, after 
oxidation with CHL oxidase form hydrogen peroxide. The peroxide reacts with phenol, 
4-aminoantipyrine via oxidation catalyzed by peroxidase, yielding a red-colored 
substance (quinonimine) that allow measure the CHL by absorbance. But just like in TG 
quantification, when colorimetric assays are used to evaluate suspensions of insoluble fat, 
the solubilization must be effective for the cleavage to occur completely and yield an 
accurate measure. We observed that when analyzing total lipid extracts, the results were 
not reproducible, even in the control sample (Figure 24). 
 
 
Figure 24. Quantification of CHL in total lipid extract from cells treated with 
different FAs. CHL values (mg/dL) were normalized to protein content and related to 
the untreated control. Mean +/- SD from three independent experiments t-test was used 
to analyze significant changes. 
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So, a pilot test was conducted with the same conditions as the TG pilot test (Figure 
25). The condition more effective was the buffer mixed with 5% of Triton X100 with a 
dilution of 1/3. However, we could not accurately measure the concentration present in 
the sample and the measurement of concentration of CHL was repeated (Figure 26). 
 
 
 
 
Figure 25. Pilot test to see which condition better solubilized the sample. The samples 
had a known concentration of CHL (200 mg / dL). Legend: A1 - Ammonium hydrogen 
carbonate buffer 5 mM pH 7.4 dilution than 1/5; A2 - Ammonium hydrogen carbonate 
buffer 5 mM pH 7.4 with 5% Triton X100 at a dilution 1/5; B1 - Ammonia hydrogen 
carbonate buffer 5 mM pH 7.4 at a dilution 1/3; B2 - Ammonium hydrogen carbonate 
buffer 5 mM pH 7.4 with 5% Triton X100 at a dilution 1/3. Mean +/- SD is shown. 
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Figure 26. Quantification of CHL in total lipid extract from cells treated with 
different FAs. CHL values (mg/dL) were normalized to protein content and related to 
the untreated control. Mean +/- SD from three independent experiments t-test was used 
to analyze significant changes. 
 
The results were not reproducible and none showed significant differences when 
compared to other groups so curiously, this approach worked to the TG but not for CHL. 
Therefore, another approach should be implemented to measure the total CHL. It could 
be measured by a multistep process in which the lipids are first extracted with organic 
solvents, like we did in our stud, in order to have a total lipid extract. This step would be 
followed by chromatographic methods such as TLC to separate the CHL and then the 
quantitative analysis of the samples. This is more laborious and requires the use of strong 
acids and other dangerous chemicals so the use of enzymatic reagents for tissue lipid 
analysis was clearly more desirable and faster however in the case of CHL, it is not the 
most recommended.  
 
8. Effect of fatty acids on the relative levels of phospholipid classes 
Many cellular functions and responses are affected when the membrane lipid 
composition is modified because membrane fluidity and structure changes. These 
alterations may affect the conformation of certain transporters, receptors, and enzymes 
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that are sensitive to changes in the structure of their lipid microenvironment, leading to 
changes in protein activity (85). 
In order to see if exogenous FAs affect PL of membranes, quantification of each 
PL class were performed. Each PL class was separated from the total lipid extract by TLC 
a very valuable technique, which is fast and simple (90). Identification of PL classes was 
carried out by comparison with known standards also applied in the TLC plate. The 
classes identified were LPC, SM, PC, PI, PS, PE and CL (Figure 27). 
 
 
Figure 27. Representative TLC separation of 30 ug total lipid extract obtained from 
T-47D cell line treated with different FAs. Lane 1-2 – Control extract; Lane 3- PA, PI 
and LPC standards; Lane 4-5 – OA1 extract; Lane 6 – CL, PE and PC standards; Lane 7-
8 -  LA1 extract; Lane 9 – PG, PS and SM standards; Lane 10-11 – LA 2 extract. 
Abbreviations: PC  - Phosphatidylcholine;  PS  -  Phosphatidylserine;  PE  -  
Phosphatidylethanolamine;  SM  - Sphingomyelin;  PG  -  Phosphatidylglycerol;    PI  -  
Phosphatidylinositol;  PA  -  Phosphatidic  Acid;  CL  - Cardiolipin; LPC – 
Lysophosphatidylcholine; OA1 – Oleic acid 1 ug/mL (18:1 n-9) ; LA1 – Linoleic acid 
1ug/mL (18:2 n-6); LA2 - Linoleic acid 2 ug/mL. 
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 After the separation of each PL class, the spots were scratched and the amount of 
phosphorous in each spot was quantified. Thereafter the % of each class was calculate 
relative to total PL. The results obtained are shown in Table 2.  
 
Table 2 Percent (%) of each class of PL in three independent experiments (R1, R2 
and R3). Values in bold were not included in the graph. 
 
 
Values in bold represent values excluded to perform the graph because there are 
very different from other values in the same sample and are most probably related to 
errors in the methodology. The results are represented in Figure 28. 
 
 
 
Classes R2 R2
LPC 1,4013 4,7375 6,2720 4,7421 4,0431 2,3437 3,6400 7,1049 3,6531 3,0367
SM 7,8655 6,3605 6,4408 8,6244 6,9872 6,6332 9,0768 7,6400 8,6751 8,1178
PC 32,9536 36,7529 30,7696 30,0278 34,6125 36,8363 38,8816 29,8168 28,9044 34,3462
PI 12,8831 11,3473 14,1754 11,8596 11,3775 13,6201 9,0486 11,2668 11,8391 11,2998
PS 10,9032 13,1276 13,4722 10,8823 12,3986 10,2751 13,8183 16,9745 14,1792 15,1195
PE 17,1775 18,0768 15,7223 21,9872 17,9635 17,0694 17,5829 16,3502 20,9012 18,3544
CL 16,8158 9,5973 13,1477 11,8766 12,6176 13,2222 7,9519 10,8467 11,8480 9,7257
Classes R2 R2
LPC 1,4013 4,7375 6,2720 4,7421 4,0431 4,4132 5,8304 5,9136 5,4703 2,5639
SM 7,8655 6,3605 6,4408 8,6244 6,9872 8,6379 6,5626 7,4467 7,0772 6,4228
PC 32,9536 36,7529 30,7696 30,0278 34,6125 40,6621 36,2977 30,0059 28,4222 32,9590
PI 12,8831 11,3473 14,1754 11,8596 11,3775 8,8642 9,6843 12,3747 13,6022 12,7279
PS 10,9032 13,1276 13,4722 10,8823 12,3986 8,4915 13,3809 15,6600 11,8621 13,3726
PE 17,1775 18,0768 15,7223 21,9872 17,9635 15,6915 20,4667 19,3833 22,9658 21,5640
CL 16,8158 9,5973 13,1477 11,8766 12,6176 13,2397 7,7775 9,2158 10,6002 10,3898
Classes R2 R2
LPC 1,4013 4,7375 6,2720 4,7421 4,0431 4,9458 3,6278 5,3407 4,2743 3,1355
SM 7,8655 6,3605 6,4408 8,6244 6,9872 8,6551 6,7703 7,8430 7,5810 7,3602
PC 32,9536 36,7529 30,7696 30,0278 34,6125 37,3758 39,1786 29,8781 29,2822 32,4699
PI 12,8831 11,3473 14,1754 11,8596 11,3775 10,7747 10,5092 14,4162 9,9826 10,0760
PS 10,9032 13,1276 13,4722 10,8823 12,3986 7,8676 12,8887 17,1799 18,0112 13,7899
PE 17,1775 18,0768 15,7223 21,9872 17,9635 18,7939 19,0772 16,2462 17,9936 21,2499
CL 16,8158 9,5973 13,1477 11,8766 12,6176 11,5872 7,9482 9,0958 12,8751 11,9187
R1 R3 R1 R3
R1 R3
R1
R1 R3
% retative content of PL
Control LA1
R3 R1 R3
Control OA1
% retative content of PL
% retative content of PL
Control LA2
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Figure 28. Relative PL content (%) in each class of T-47D cell line treated with 
different FAs. PL classes were separated by TLC and phosphorous content in each spot 
was related to total phosphorous content in the sample. The results are presented as mean 
+/- SEM from three independent experiments is shown. Statistical significance was 
measured with One-way ANOVA and Dunnett’s post-hoc test *: p<0.05, **: p<0.01. 
 
The most abundant PL class in all treatments was PC, followed by PE. Cells treated 
with LA1 showed an increase in the level of PE, while cells treated with LA2 showed an 
increase in PS. A decrease in LPC in cells treated with OA was observed. Finally, in CL 
it was observed a tendency to decrease in all treatments, especially in LA1, and PI was 
also decreased in LA2. However, these differences were not statistically significant. So, 
although there are slight changes in PL classes only LPC, PS and PE were significantly 
changed by OA, LA2 and LA1, respectively. A study of Doria et al (2012) that compared 
the profile of PLs from mice mammary epithelial and breast cancer cell lines, showed that 
decreased levels of LPC are associated to less malignancy, which is in agreement with 
the results presented. PS levels didn’t showed differences (67). Another study of Doria et 
al (2013), which compared the profile of PLs from human mammary epithelial and breast 
cancer cell lines, showed that relative content of LPC where similar in all cell lines. Also, 
the PS relative amounts showed an increase in malignant cells but it wasn’t statistically 
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significant. Curiously, in both studies PE was found increased in non-malignant cells 
when compared with malignant cells (91).  
Based on the PL class biosynthetic pathways, we can speculate on possible enzymes 
regulated by the FA treatment. In Figure 29 the main pathways of PL metabolism are 
presented.  
 
Figure 29. Main pathways of biosynthesis of PLs. PA: Phosphatidic acid, PC:   
phosphatidylcholine, PE: phosphatidylethanolamine, PG: phosphatidylglycerol, PI:  
phosphatidylinositol, PS: phosphatidylserine, LPC: lysophosphatidylcholine, CL: 
cardiolipin, SM: sphingomyelin, CDP: cytidine diphosphate, DAG: diacylglycerol,PIP: 
phosphatidylinositol phosphate. PLD: phospholipase D, PLA2: phospholipase A2, 
LPCAT1: lysophosphatidylcholine acyltrasferase1, PSD: 
phosphatidylserinedescarboxilase, PSS1: phosphatidilserine synthase 1, PSS2: 
phosphatidilserine synthase 2, S: sphyngomielinase, SMS: sphyngomilelin synthase, 
CDP-DIP: CDP-DAG inositol phosphatidyltransferase, EPT: CDP–ethanolamine: DAG 
ethanolamine phosphotransferase, ET: CTP:phosphoethanolamine cytidylyltransferase, 
EK: ethanolamine kinase. Note: this scheme is a compilation of information based on 
literature referred on this section. 
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PE plays a major role in membrane curvature and this influences structure, folding, 
and activity of membrane proteins. Synthesis of PE can occur by two pathways. The first 
requires using the ethanolamine as the substrate. Ethanolamine is activated by 
phosphorylation to form the headgroup of PE, the phosphoethanolamine by ethanolamine 
kinase (EK) and then phosphoethanolamine reacts with CTP and couple with cytidine-
diphosphate (CDP) through the action of CTP: phosphoethanolamine cytidylyltransferase 
(ET). In the final step, phosphoethanolamine from CDP-phosphoethanolamine is attached 
to the sn-3 position of DAG to yield PE by CDP-ethanolamine: DAG ethanolamine 
phosphotransferase (EPT) (92). The second pathway involves the decarboxylation of PS 
by the PS decarboxylase (Figure 29). In the case of LA1 treatment, the increase verified 
in PE class could be caused by the increase of ethanolamine phosphorylation (by EK) 
(93). These reasons are more probable than PS descarboxilation because the levels of PS 
did not decrease, in fact it could be seen a slight increase of PS in LA1 treatment. 
PS is a PL that is present in the inner leaflet of the cell membrane and have other 
important functions like an essential cofactor that binds to activate the protein kinase C, 
that is a key enzyme involved in the signal transduction. PS  is increased with LA2 
treatment that may be associated with PE metabolism, by action of PSS2. So expression 
of this enzyme may be induced in T-47D cells treated with LA2. 
LPC can be derived from PC (Figure 29) due to the action of phospholipase A2. It 
has been proposed that LPC can stimulate cell signaling and cell migration through its 
action as an extracellular ligand to specific receptors (coupled to G proteins). Further 
signaling effect may activates the specific phospholipase C, which will releases DAG and 
inositol triphosphate with resultant increases in intracellular Ca2+ and activation of protein 
kinase C or by the action of autotaxin (ATX). LPC can be converted to LPA, a potent 
signaling molecule, by the action ATX via it lysophospholipase D activity. Both LPC as 
the LPA can lead to a stimulation of cell proliferation and migration (94). For example, 
ATX is found in extracellular fluid surrounding the tumors , this enzyme is associated to 
invasiveness and higher plasma LPA and LPC levels on patients with ovarian and breast 
cancer, compared with healthy controls (95,96). Therefore, it was hypothesize that the 
decrease of the total content of this class in cells treated with OA could reduce the action 
of these PL, leading to a decrease of LPA and consequently lower stimulation of 
proliferation. 
In summary, the PS and PE are altered in a medium supplemented with LA altering 
the structure of the membrane. The conformation or quaternary  structures  of  certain  
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transporters, receptors and enzymes located in membranes are sensitive to changes  in  
the  structure  of  their  lipid  microenvironment, and that might affect a number of cellular 
functions, that could lead to cell growth and proliferation. We speculate that 18:2 n-6 
increased in the LA1 and LA2 treatment may be esterified PS and PE in these samples, 
which in turn can be related to the increased metabolic activity/cell number. The decrease 
of TG can be due to beta-oxidation to provide energy for cell growth and metabolism. 
LPC is altered in OA medium, which could be related to a decrease of stimulation of cell 
proliferation in breast cancer cells, through the decrease of production of metabolites that 
enhance the cell proliferation like LPA. 
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IV. Conclusion 
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IV. Conclusion 
 
The aim of this work was to evaluate if the lipidome of the T47-D breast cancer cell 
line may be modified by different dietary FAs supplementation and to try to evaluate if 
these changes could affect viability, growth and apoptosis.  
The lipidomic methods used showed to be valuable for analysis of fatty acids effects 
on cancer cells. With this approach, it was possible to identify differences in the lipidome 
of cancer cells treated with OA or LA when compared to control. An increase of relative 
amounts of PE and PS were found in cells treated with LA and the increase of the FA 
18:2 in cells was also observed. Furthermore, a decrease of LPC was found in cells treated 
with OA. Also total  TGs  were  decreased  in  cells  treated  with  LA2. Therefore it was 
possible to conclude that supplementation with LA is associated with significant changes 
in lipidome that may be related to the effects on cell survival and integrity, and that OA 
may have the opposite effect, due to an increase of apoptosis. 
Finally, this  work  contributes  to  a  better  understanding  of  the  influence of 
dietary FAs on the lipidome of T-47D cells and this alterations are involved on changes 
in cell number and apoptosis, being LA associated to a stimulation of growth of this cells 
and OA associated with inhibition of cell growth. These findings may lead to new 
perspectives in the identification of specific mechanisms that may be helpful to 
understand the process behind this disease. Nevertheless, more studies are necessary to 
take more conclusions about how FAs promote the effects observed.   
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V. Future Perspectives 
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V. Future perspectives 
 
 In the future, this work could be completed by a more detailed analysis of the 
lipidome by using LC-MS. This approach will allow to identify the modifications at the 
molecular level, as well as if the dietary FA supplemented are being incorporated in any 
specific class of PLs. Thus, identification of PL classes and the changes in their fatty acyl 
chains will open new possibilities to exploration of these alterations in cancer. From these 
relation new biomarkers might arise to prevent cancer and a basis to research and develop 
new therapeutic opportunities. 
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